(Q45180417)

English

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

scientific article published on 26 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

0 references

myocardial infarction

1 reference

based on heuristic

inferred from title

Frans Van de Werf

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Eugene Braunwald

3

object named as

Eugene Braunwald

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Michał Tendera

11

object named as

Michal Tendera

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sabina A Murphy

9

object named as

Sabina A Murphy

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Benjamin M Scirica

1

object named as

Benjamin M Scirica

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

2

object named as

Marc P Bonaca

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Marc S Sabatine

10

object named as

Marc S Sabatine

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

author name string

Gaetano M De Ferrari

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Daniel Isaza

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Basil S Lewis

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Felix Mehrhof

7

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Piera A Merlini

8

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Robert Wilcox

13

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

David A Morrow

14

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

TRA 2°P-TIMI 50 Steering Committee Investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

0 references

publication date

26 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

380

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

9850

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1317-1324

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

One-year cardiovascular event rates in outpatients with atherothrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Vorapaxar in the secondary prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acut

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associati

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous co

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961269-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(12)61269-0

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45180417&oldid=2112378182"